GYOEDU

ICON 2

ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer

Date of Publication:

November 14, 1998

Pubmed Link:

https://pubmed.ncbi.nlm.nih.gov/9843101/

Hypothesis:

Does single agent carboplatin improve survival in women with epithelial ovarian cancer?

Control Arm(s):

cyclophosphamide 500mg/m2doxorubicin 50mg/m2cisplatin 50mg/m2

Experimental Arm(s):

carboplatin AUC 5

Primary End Point:

Inclusion Criteria:

clinician certain chemotherapy is neededepithelial ovarian cancer

Exclusion Criteria:

Results:

carboplatin (n=760) vs combo (n=766):77% stage III or IV~80% in both arms completed 6 cyclesmore leukopenia/nausea in combo armmore thrombocytopenia with carboplatinmedian f/u: 35 mosmedian PFS: 15.5 vs 17 mos (NS)median OS: 33 vs 33 mos (NS)

Conclusions:

Single agent carboplatin is effective and safe for women with epithelial ovarian cancer

Reviewer:

Olga T Filippova